Cargando…
Allogeneic vs. autologous mesenchymal stem/stromal cells in their medication practice
Mesenchymal stem/stromal cell (MSC)-based therapeutics is already available for treatment of a range of diseases or medical conditions. Autologous or allogeneic MSCs obtained from self or donors have their own advantages and disadvantages in their medical practice. Therapeutic benefits of using auto...
Autores principales: | Li, Chenghai, Zhao, Hua, Cheng, Linna, Wang, Bin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561357/ https://www.ncbi.nlm.nih.gov/pubmed/34727974 http://dx.doi.org/10.1186/s13578-021-00698-y |
Ejemplares similares
-
Mesenchymal stem/stromal cells: Developmental origin, tumorigenesis and translational cancer therapeutics
por: Li, Chenghai, et al.
Publicado: (2020) -
Mesenchymal Stem/Stromal Cells in Progressive Fibrogenic Involvement and Anti-Fibrosis Therapeutic Properties
por: Li, Chenghai, et al.
Publicado: (2022) -
Mesenchymal Stem Cells: Allogeneic MSC May Be Immunosuppressive but Autologous MSC Are Dysfunctional in Lupus Patients
por: Cheng, Rui-Juan, et al.
Publicado: (2019) -
Mesenchymal Stem Cells in Systemic Sclerosis: Allogenic or Autologous Approaches for Therapeutic Use?
por: Rozier, Pauline, et al.
Publicado: (2018) -
Novel therapies using cell sheets engineered from allogeneic mesenchymal stem/stromal cells
por: Kondo, Makoto, et al.
Publicado: (2020)